Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Jose Banchs

Concepts (264)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Echocardiography
16
2021
625
3.410
Why?
Heart Diseases
13
2024
345
2.440
Why?
Neoplasms
23
2024
2465
2.190
Why?
Echocardiography, Transesophageal
5
2019
85
1.240
Why?
Anthracyclines
6
2024
46
1.170
Why?
Ventricular Dysfunction, Left
7
2022
386
1.170
Why?
Heart Ventricles
7
2023
766
1.150
Why?
Ventricular Function, Left
7
2022
525
1.130
Why?
Heart Neoplasms
3
2018
49
0.970
Why?
Cardiovascular Diseases
8
2022
2018
0.940
Why?
Antineoplastic Agents
10
2019
2058
0.920
Why?
Atrial Flutter
1
2023
35
0.830
Why?
Cardiovascular System
2
2023
139
0.790
Why?
Atrial Fibrillation
3
2023
378
0.780
Why?
Cardiotoxicity
9
2024
33
0.760
Why?
Stroke Volume
7
2022
588
0.740
Why?
Cardiology
4
2020
267
0.730
Why?
Sarcoma
3
2023
177
0.710
Why?
Medical Oncology
5
2020
272
0.690
Why?
Heart Function Tests
2
2019
60
0.650
Why?
Practice Patterns, Nurses'
1
2018
19
0.600
Why?
Osteosarcoma
1
2019
73
0.600
Why?
Thrombosis
2
2018
321
0.580
Why?
Endocarditis
2
2021
32
0.570
Why?
Thrombocytopenia
1
2019
182
0.560
Why?
Tachycardia, Sinus
1
2016
2
0.550
Why?
Diagnostic Imaging
3
2018
330
0.530
Why?
Pericardial Effusion
4
2019
20
0.520
Why?
Echocardiography, Three-Dimensional
2
2018
40
0.510
Why?
Education, Medical, Continuing
1
2016
124
0.490
Why?
Cardiomyopathies
2
2016
335
0.490
Why?
Recovery of Function
2
2016
643
0.480
Why?
Takotsubo Cardiomyopathy
1
2015
3
0.480
Why?
Pericarditis
1
2014
11
0.470
Why?
Rural Population
1
2018
504
0.460
Why?
Fibroma
1
2014
23
0.460
Why?
Heart
4
2023
638
0.450
Why?
Aortic Aneurysm
1
2014
63
0.450
Why?
Radiotherapy
1
2015
185
0.440
Why?
Radiation Injuries
1
2015
137
0.430
Why?
Breast Neoplasms
7
2022
2139
0.410
Why?
Humans
62
2024
128524
0.410
Why?
Heart Valve Prosthesis Implantation
1
2014
171
0.400
Why?
Multimodal Imaging
4
2018
105
0.400
Why?
Cardiovascular Infections
1
2012
2
0.390
Why?
Vascular Diseases
1
2015
236
0.380
Why?
Tongue Neoplasms
1
2012
23
0.380
Why?
Cardiac Tamponade
3
2016
14
0.370
Why?
Myocarditis
1
2012
97
0.370
Why?
Tracheoesophageal Fistula
1
2011
33
0.370
Why?
Radiography, Interventional
1
2011
101
0.360
Why?
Fluoroscopy
1
2011
155
0.360
Why?
Ultrasonography, Interventional
1
2011
127
0.350
Why?
Mass Screening
1
2018
1152
0.350
Why?
Middle Aged
24
2022
30893
0.340
Why?
Trastuzumab
5
2016
100
0.320
Why?
Female
33
2024
68127
0.310
Why?
Male
29
2024
62883
0.310
Why?
Quality Improvement
1
2016
1100
0.300
Why?
Echocardiography, Doppler, Color
3
2015
35
0.290
Why?
Stents
1
2011
504
0.280
Why?
Early Diagnosis
3
2018
236
0.280
Why?
Coronary Artery Disease
3
2021
677
0.270
Why?
Carcinoma, Squamous Cell
1
2012
620
0.270
Why?
Heart Failure
4
2023
2150
0.260
Why?
Risk Factors
12
2024
9727
0.250
Why?
Prognosis
8
2023
3780
0.240
Why?
Heart Conduction System
2
2015
94
0.230
Why?
Troponin I
3
2015
75
0.230
Why?
Predictive Value of Tests
8
2022
1936
0.220
Why?
Esophageal Neoplasms
2
2020
292
0.220
Why?
Circulating MicroRNA
1
2023
25
0.210
Why?
Lung Neoplasms
4
2020
2323
0.210
Why?
Retrospective Studies
14
2022
14460
0.200
Why?
Antineoplastic Combined Chemotherapy Protocols
3
2019
1565
0.200
Why?
Fatal Outcome
2
2015
301
0.200
Why?
Texas
4
2021
227
0.200
Why?
Electrocardiography
2
2015
607
0.190
Why?
Mitogen-Activated Protein Kinase 7
1
2021
21
0.190
Why?
Adult
16
2024
35315
0.190
Why?
Biomarkers
7
2023
3881
0.190
Why?
Poly(ADP-ribose) Polymerases
1
2021
87
0.180
Why?
Ultrasonography
3
2015
723
0.180
Why?
Catheters, Indwelling
1
2021
74
0.180
Why?
Doxorubicin
3
2023
322
0.180
Why?
Lymphoma, Large B-Cell, Diffuse
1
2022
113
0.180
Why?
Radiation, Ionizing
1
2020
75
0.170
Why?
Ventricular Dysfunction, Right
1
2023
224
0.170
Why?
Aged
13
2022
21971
0.170
Why?
Cancer Survivors
1
2024
263
0.160
Why?
Graft vs Host Disease
1
2021
237
0.160
Why?
ROC Curve
2
2021
501
0.160
Why?
Shock, Septic
1
2021
206
0.160
Why?
Radiotherapy, Intensity-Modulated
1
2020
127
0.160
Why?
Pericardiocentesis
1
2019
9
0.160
Why?
Carcinoma, Non-Small-Cell Lung
2
2020
1044
0.160
Why?
Erdheim-Chester Disease
1
2018
5
0.160
Why?
Systole
2
2016
191
0.160
Why?
Antibiotics, Antineoplastic
3
2024
120
0.150
Why?
Cardiac Imaging Techniques
1
2018
20
0.150
Why?
Myxoma
1
2018
12
0.150
Why?
Follow-Up Studies
5
2021
4898
0.150
Why?
Carcinoid Heart Disease
1
2017
2
0.140
Why?
Echocardiography, Doppler
1
2018
110
0.140
Why?
Reproducibility of Results
3
2016
3023
0.140
Why?
Staphylococcus aureus
1
2021
425
0.140
Why?
MicroRNAs
1
2023
671
0.140
Why?
Multiple Myeloma
1
2018
123
0.130
Why?
Antineoplastic Agents, Immunological
1
2019
173
0.130
Why?
Staphylococcal Infections
1
2021
380
0.130
Why?
Academies and Institutes
1
2016
48
0.130
Why?
Oligopeptides
1
2018
257
0.130
Why?
Myocardial Ischemia
1
2018
249
0.130
Why?
Pericarditis, Constrictive
1
2016
2
0.130
Why?
Hematopoietic Stem Cell Transplantation
1
2021
573
0.130
Why?
Cardiotoxins
1
2015
4
0.130
Why?
Withholding Treatment
1
2016
70
0.120
Why?
Genetic Predisposition to Disease
1
2024
2266
0.120
Why?
Clinical Decision-Making
1
2018
302
0.120
Why?
Sepsis
1
2021
556
0.120
Why?
Cardiotonic Agents
1
2016
124
0.120
Why?
Thrombolytic Therapy
1
2016
132
0.120
Why?
Antibodies, Monoclonal, Humanized
3
2015
759
0.120
Why?
Ventricular Dysfunction
1
2015
15
0.120
Why?
Pulmonary Surgical Procedures
1
2014
8
0.120
Why?
Daptomycin
1
2014
18
0.120
Why?
Cefazolin
1
2014
16
0.120
Why?
Pericardium
1
2015
54
0.120
Why?
Comorbidity
3
2019
1540
0.120
Why?
Carotid Artery Diseases
1
2015
65
0.120
Why?
Dexmedetomidine
1
2014
39
0.110
Why?
Preoperative Care
2
2015
342
0.110
Why?
Chemotherapy, Adjuvant
1
2015
376
0.110
Why?
Amyloidosis
1
2014
39
0.110
Why?
Pulmonary Embolism
1
2016
208
0.110
Why?
Young Adult
4
2024
12320
0.110
Why?
Survival Rate
4
2021
1872
0.110
Why?
Heart Valve Prosthesis
1
2014
111
0.110
Why?
Peroxidase
1
2013
169
0.110
Why?
Postoperative Complications
2
2015
2479
0.100
Why?
Myocardium
1
2018
970
0.100
Why?
Cardiopulmonary Resuscitation
1
2016
260
0.100
Why?
Chemoradiotherapy
1
2014
209
0.100
Why?
Coronary Vessels
1
2015
235
0.100
Why?
Hodgkin Disease
1
2015
134
0.100
Why?
Radiopharmaceuticals
1
2013
164
0.100
Why?
Fluorodeoxyglucose F18
1
2013
124
0.100
Why?
Decision Trees
1
2012
89
0.100
Why?
Heart Arrest
1
2016
327
0.100
Why?
Incidence
4
2021
2619
0.100
Why?
Positron-Emission Tomography
1
2013
281
0.100
Why?
Hypertension, Pulmonary
1
2023
1735
0.090
Why?
Antibiotic Prophylaxis
1
2012
94
0.090
Why?
Endocarditis, Bacterial
1
2012
41
0.090
Why?
Aortic Valve
1
2014
350
0.090
Why?
Cardiac Catheterization
1
2015
512
0.090
Why?
Radiosurgery
1
2013
317
0.090
Why?
Prosthesis Implantation
1
2011
143
0.090
Why?
Risk Assessment
3
2018
3256
0.080
Why?
Combined Modality Therapy
3
2018
1209
0.080
Why?
Anti-Inflammatory Agents
1
2012
469
0.080
Why?
Sensitivity and Specificity
2
2011
1820
0.080
Why?
Aged, 80 and over
4
2015
7040
0.070
Why?
Myocardial Infarction
1
2015
1014
0.070
Why?
Animals
5
2023
34501
0.070
Why?
Treatment Outcome
4
2018
10163
0.070
Why?
Antiviral Agents
1
2012
704
0.070
Why?
Adolescent
3
2024
20213
0.060
Why?
Palliative Care
1
2012
716
0.060
Why?
Prevalence
1
2011
2549
0.060
Why?
Troponin
1
2023
50
0.050
Why?
Natriuretic Peptide, Brain
2
2015
99
0.050
Why?
Taxoids
2
2013
95
0.050
Why?
Anti-Bacterial Agents
1
2012
1667
0.050
Why?
Ribose
1
2021
21
0.050
Why?
Cell- and Tissue-Based Therapy
1
2022
74
0.050
Why?
Antigens, CD19
1
2022
114
0.050
Why?
Adenosine Diphosphate
1
2021
78
0.050
Why?
Poly (ADP-Ribose) Polymerase-1
1
2021
39
0.050
Why?
Cyclophosphamide
1
2021
231
0.050
Why?
Mitral Valve Insufficiency
1
2001
67
0.050
Why?
Feedback
1
2021
159
0.040
Why?
Pulmonary Circulation
1
2023
415
0.040
Why?
Ventricular Function, Right
1
2023
272
0.040
Why?
Tertiary Care Centers
1
2021
147
0.040
Why?
Myocytes, Cardiac
1
2024
491
0.040
Why?
Radiotherapy Dosage
1
2020
248
0.040
Why?
Poly-ADP-Ribose Binding Proteins
1
2019
33
0.040
Why?
Peptide Fragments
2
2015
685
0.040
Why?
United States
4
2019
13876
0.040
Why?
DNA Topoisomerases, Type II
1
2019
44
0.040
Why?
Immunocompromised Host
1
2021
195
0.040
Why?
Exercise Therapy
1
2023
414
0.040
Why?
Multivariate Analysis
2
2014
1494
0.040
Why?
Immunotherapy, Adoptive
1
2022
295
0.040
Why?
Societies
1
2018
36
0.040
Why?
Logistic Models
2
2015
1975
0.040
Why?
Hemangiosarcoma
1
2018
20
0.040
Why?
Positron Emission Tomography Computed Tomography
1
2018
82
0.040
Why?
DNA Damage
1
2020
364
0.040
Why?
Receptors, Antigen, T-Cell
1
2022
701
0.040
Why?
Arterial Occlusive Diseases
1
2018
79
0.040
Why?
Reference Values
1
2018
780
0.030
Why?
Phosphorylation
1
2021
1681
0.030
Why?
Program Development
1
2019
362
0.030
Why?
Interprofessional Relations
1
2019
270
0.030
Why?
Practice Guidelines as Topic
2
2014
1490
0.030
Why?
Molecular Targeted Therapy
1
2019
387
0.030
Why?
Polymorphism, Single Nucleotide
1
2024
2065
0.030
Why?
Prospective Studies
2
2022
7043
0.030
Why?
Morbidity
1
2017
302
0.030
Why?
Mice
2
2023
16579
0.030
Why?
Cytokines
1
2023
1985
0.030
Why?
Galectin 3
1
2015
21
0.030
Why?
Mitochondria
1
2021
844
0.030
Why?
Growth Differentiation Factor 15
1
2015
39
0.030
Why?
Recurrence
1
2018
1001
0.030
Why?
Vascular Endothelial Growth Factor Receptor-1
1
2015
66
0.030
Why?
Program Evaluation
1
2019
874
0.030
Why?
Biopsy
1
2018
1085
0.030
Why?
Secondary Prevention
1
2016
220
0.030
Why?
Adrenergic alpha-2 Receptor Agonists
1
2014
24
0.030
Why?
Intraoperative Care
1
2014
45
0.030
Why?
Breast
1
2015
152
0.030
Why?
Diastole
1
2015
151
0.030
Why?
Global Health
1
2017
326
0.030
Why?
SEER Program
1
2015
206
0.030
Why?
Oxidative Stress
1
2020
1188
0.030
Why?
Drug Monitoring
1
2015
184
0.030
Why?
Clinical Trials, Phase I as Topic
1
2014
49
0.030
Why?
Ohio
1
2014
153
0.030
Why?
Europe
1
2014
362
0.030
Why?
Clinical Trials as Topic
1
2018
998
0.030
Why?
Acute Disease
1
2016
968
0.030
Why?
Amyloid
1
2014
83
0.030
Why?
Phenotype
1
2021
3050
0.030
Why?
C-Reactive Protein
1
2015
396
0.030
Why?
Anesthesia
1
2014
129
0.020
Why?
Time Factors
2
2013
6503
0.020
Why?
Interleukin-1 Receptor-Like 1 Protein
1
2012
26
0.020
Why?
Radiology
1
2014
160
0.020
Why?
Odds Ratio
1
2015
1022
0.020
Why?
Disease Management
1
2016
588
0.020
Why?
Action Potentials
1
2015
469
0.020
Why?
Consensus
1
2014
633
0.020
Why?
North America
1
2012
289
0.020
Why?
Kaplan-Meier Estimate
1
2014
857
0.020
Why?
Neoplasm Staging
1
2015
1288
0.020
Why?
Chi-Square Distribution
1
2012
512
0.020
Why?
Pilot Projects
1
2016
1558
0.020
Why?
Age Factors
1
2018
3117
0.020
Why?
Myocardial Contraction
1
2012
331
0.020
Why?
Societies, Medical
1
2014
749
0.020
Why?
Receptors, Cell Surface
1
2012
371
0.020
Why?
Patient Selection
1
2014
661
0.020
Why?
Longitudinal Studies
1
2015
2697
0.020
Why?
Magnetic Resonance Imaging
1
2018
3366
0.020
Why?
Cross-Sectional Studies
1
2015
5040
0.010
Why?
Cohort Studies
1
2013
5369
0.010
Why?
Mitral Valve
1
2001
85
0.010
Why?
Confidence Intervals
1
2001
318
0.010
Why?
Probability
1
2001
308
0.010
Why?
Observer Variation
1
2001
315
0.010
Why?
Severity of Illness Index
1
2001
2736
0.010
Why?
Banchs's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)